A Nonparametric Population Pharmacokinetic Model of Selumetinib in Pediatric Patients Diagnosed With Neurofibromatosis-I or Plexiform Neurofibromas.

ABSTRACT: A twice-daily administration of oral selumetinib (SLT) in the fasted state is the only approved pharmaceutical option for treating inoperable neurofibromatosis type I (NF-1) and plexiform neurofibromas (PN). In children, exposure to SLT is highly variable, and fasting presents a substantial burden. Therapeutic drug monitoring and pharmacokinetic modeling can support individualized therapy accompanied by a more rational alimentary routine. Twenty-eight children diagnosed with inoperable NF-1 or PN were recruited at a major pediatric oncological center. Twenty-two patients donated 156 blood samples in steady state for nonparametric population pharmacokinetic modeling. An equation was developed experimentally for estimating model error. Eleven three-compartment models were compared in terms o

SUBMITTER: Kollo Z 

PROVIDER: S-EPMC12823296 | biostudies-literature | 2026 Jan

REPOSITORIES: biostudies-literature